ROCKVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, ...
- LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant CMV Infection/Disease Refractory* to Conventional ...
− If Approved, Maribavir Will Be the First and Only Treatment Indicated for Post-Transplant Cytomegalovirus (CMV) Infection in Those That Are Refractory, With or Without Resistance (R/R) − NDA based ...
Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates. The Food and Drug Administration (FDA) has approved Livtencity ...
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for ...
− If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population − CMV is one of the most common infections experienced by transplant recipients ...
Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been infected by age 40. A healthy immune system can keep ...
Credit: Getty Images This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of CMV infection in solid organ transplant recipients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback